FAIRLANE, a double-blind placebo-controlled randomized phase II trial of neoadjuvant ipatasertib plus paclitaxel for early triple-negative breast cancer-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

FAIRLANE, a double-blind placebo-controlled randomized phase II trial of neoadjuvant ipatasertib plus paclitaxel for early triple-negative breast cancer

Published:2019-08 Issue:8 Volume:30 Page:1289-1297
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Oliveira M.,Saura C.,Nuciforo P.,Calvo I.,Andersen J.,Passos-Coelho J.L.,Gil Gil M.,Bermejo B.,Patt D.A.,Ciruelos E.,de la Peña L.,Xu N.,Wongchenko M.,Shi Z.,Singel S.M.,Isakoff S.J.

Funder

F. Hoffmann-La Roche Ltd

SOLTI Breast Cancer Research Group

Philips Healthcare

Roche/Genentech

Boehringer-Ingelheim

AstraZeneca

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/advance-article-pdf/doi/10.1093/annonc/mdz177/28912369/mdz177.pdf

Reference15 articles.

1. Clinical implications of molecular heterogeneity in triple negative breast cancer;Lehmann;Breast,2015

2. Management of breast cancer with targeted agents: importance of heterogeneity;Di Cosimo;Nat Rev Clin Oncol,2010

3. The molecular landscape of high-risk early breast cancer: comprehensive biomarker analysis of a phase III adjuvant population;Wilson;NPJ Breast Cancer,2016

4. Targeting activated Akt with GDC-0068, a novel selective Akt inhibitor that is efficacious in multiple tumor models;Lin;Clin Cancer Res,2013

5. AKT/PKB signaling: navigating downstream;Manning;Cell,2007

Cited by 97 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Small molecule agents for triple negative breast cancer: Current status and future prospects;Translational Oncology;2024-03

2. Current and future trends in neoadjuvant immunotherapy for the treatment of triple-negative breast cancer;Immunotherapy;2024-03

3. Endogenous pAKT activity is associated with response to AKT inhibition alone and in combination with immune checkpoint inhibition in murine models of TNBC;Cancer Letters;2024-02

4. TRPML1 as a potential therapeutic target for triple-negative breast cancer: a review;Frontiers in Oncology;2023-12-13

5. Molecularly Targeted Therapies for Triple Negative Breast Cancer: History, Advances, and Future Directions;Clinical Breast Cancer;2023-12

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3